eClinical Tech News

HMNC Brain Health has completed patient randomization for its Phase 2b OLIVE trial, investigating the efficacy and safety of...

Ashvattha Therapeutics secured up to $50 million in extended Series B funding, led by Tribe Capital and existing investors...

Artelo Biosciences has initiated a Phase 1 clinical trial of ART26.12, its lead FABP5 inhibitor, marking the first time...

NeuroSigma, Inc. announced the completion of enrollment for the ATTENS trial, a multicenter, double-blind, placebo-controlled study evaluating the effectiveness...

Rakovina Therapeutics has achieved a significant milestone by developing a shortlist of AI-generated molecules targeting ATR, designed for central...

ORIC Pharmaceuticals announced encouraging early safety and efficacy data from a Phase 1b trial of ORIC-944 combined with apalutamide...

Ashvattha Therapeutics secured up to $50 million in extended Series B funding, led by Tribe Capital with continued support...

Rapport Therapeutics (Nasdaq: RAPP) announced positive Phase 1 results for RAP-219, a drug candidate for central nervous system disorders....

Acumen Pharmaceuticals announced positive Phase 1 clinical trial results for sabirnetug (ACU193), a potential Alzheimer’s diseaseAlzheimer’s disease treatment targeting...

Sana Biotechnology announced positive initial results from a first-in-human study involving a patient with type 1 diabetes. The study,...